James D. Rodgers - Concepedia

Author

James D. Rodgers

Also Known As

J. D. RODGERS, J. D. Rodgers, J. Rodgers, J.D. Rodgers, JAMES D. RODGERS, James D Rodgers, James D. RODGERS, James D. Rodgers, James Rodgers, Rodgers, J.D.

122

Publications

4.6K

Citations

H-Index

Concepts

All Affiliations

Wilmington University DuPont (United States)Experimental Station Incyte (United States)Janssen (United States)

About

James D. Rodgers is an author at Wilmington University specializing in pharmacology, natural sciences, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	1.4K
2	Engineering	11	11	984
3	Business	5	5	141
4	Health Sciences	1	1	12
5	Law	1	1	34

James D. Rodgers

Publications

4.1K

Citations

H-Index

Page 1

	Year	Citations
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms Alfonso Quintás‐Cardama, Kris Vaddi, Phillip Liu, Blood	2010	813
Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050 Jordan S. Fridman, Peggy Scherle, Robert J. Collins, The Journal of Immunology ImmunologyKinase InhibitorsImmunotherapyMusculoskeletal ResearchInflammatory Arthritis	2010	440
Electrochemical Oxidation of Chlorinated Phenols James D. Rodgers, Wojciech Jȩdral, Nigel J. Bunce Environmental Science & Technology Environmental ElectrochemistryChemical EngineeringEngineeringOrganic ElectrochemistryOxidation Potentials	1999	322
Inhibition of Clinically Relevant Mutant Variants of HIV-1 by Quinazolinone Non-Nucleoside Reverse Transcriptase Inhibitors Jeffrey W. Corbett, Soo S. Ko, James D. Rodgers, Journal of Medicinal Chemistry	2000	299
Enantioselective Synthesis of Janus Kinase Inhibitor INCB018424 via an Organocatalytic Aza-Michael Reaction Qiyan Lin, David Meloni, Yongchun Pan, Organic Letters EngineeringOrganic ChemistryChemistryPharmaceutical ChemistryMedicinal Chemistry	2009	167
Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) derivatives. 2 Michael J. Kukla, Henry J. Breslin, Craig J. Diamond, Journal of Medicinal Chemistry Combinatorial ChemistryBioorganic ChemistryOrganic ChemistryNew SeriesHeterocycle Chemistry	1991	166
Efficient Synthesis of 5-(Bromomethyl)- and 5-(Aminomethyl)-1-THP-Indazole Jung‐Hui Sun, Christopher A. Teleha, Jia-Sheng Yan, The Journal of Organic Chemistry Medicinal ChemistryDiversity Oriented SynthesisEngineeringBiochemistryDonut Icon	1997	127
Expanded-Spectrum Nonnucleoside Reverse Transcriptase Inhibitors Inhibit Clinically Relevant Mutant Variants of Human Immunodeficiency Virus Type 1 Jeffrey W. Corbett, Soo S. Ko, James D. Rodgers, Antimicrobial Agents and Chemotherapy Dpc 963MedicineHuman RetrovirusImmunologyPharmacology	1999	119
Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation Jordan S. Fridman, Peggy Scherle, Robert J. Collins, Journal of Investigative Dermatology InflammationTranslational MedicineAutoimmune DiseaseCutaneous BiologyReceptor Tyrosine Kinase	2011	108
Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans Adam D. Shilling, Frank M. Nedza, Thomas Emm, Drug Metabolism and Disposition	2010	107

Page 1